RxDoctor Payments Data

Minerva Perez Lopez, MD

Family Medicine · Salinas, CANPI 1710084835

Payments from drug & device makers

$393in general payments, 2019–2025

Across 11 payments — averaging $35.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Merck$105
  • Sanofi Pasteur Inc.$93
  • Novo Nordisk$84
  • AbbVie$37
  • Organon$22
  • Pfizer$20
  • plus $32 from 2 others

What the payments were for

  • Food & beverage$393100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Merck1$105
Sanofi Pasteur Inc.2$93
Novo Nordisk1$84
AbbVie2$37
Organon2$22
Pfizer1$20
Biogen1$19
Bayer1$13

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$393 in reported general payments places this provider in the 55th percentile of 10,533 family medicine providers in California.

See all family medicine providers in California

Medicare billing

Part B allowed, 2024
$20,661
Medicare patients
131
Services billed
304

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin25$30,019
TrulicityDulaglutide27$28,407
OzempicSemaglutide30$26,653
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog15$10,278
Breo ElliptaFluticasone/Vilanterol13$5,908
Atorvastatin Calcium235$3,422
Gabapentin83$2,177
Morphine Sulfate ErMorphine Sulfate12$1,834
Nano 2nd Gen Pen NeedlePen Needle, Diabetic23$1,671
Metoprolol Succinate65$1,255
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen63$1,203
Levothyroxine Sodium81$1,179
Losartan Potassium92$1,101
Omeprazole74$1,038
Oxybutynin Chloride21$1,000

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$84$26,65330 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 10,533 family medicine providers in California.

Other family medicine in Salinas

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →